期刊文献+

肺表面活性物质治疗新生儿呼吸窘迫综合征时有效减少肺出血发生率的应用时限选择的多中心回顾性研究 被引量:21

Timing for initial therapy of pulmonary surfactant to reduce pulmonary hemorrhage in neonatal respiratory distress syndrome:a multi-center retrospective study
原文传递
导出
摘要 目的探讨应用肺表面活性物质(pulmonary surfactant,PS)制剂——牛肺表面活性物质(calf pulmonary surfactant,CPS,商品名:珂立苏)治疗新生儿呼吸窘迫综合征(neonatal respiratory distress syndrome,NRDS)时有效减少肺出血发生率的最终应用时限。方法收集2008年5月至2009年6月国内22家各级医院新生儿病房应用PS治疗NRDS的相关临床资料。NRDS患儿分为3组,第1组:重度NRDS采用常规机械通气(CMV)+CPS治疗;第2组:轻度NRDS采用CMV+CPS治疗;第3组:轻度NRDS采用鼻塞式持续气道正压通气(nCPAP)+CPS治疗;将生后1、2、3、4、5、6、7、8 h作为时间界点,逐一比较在界点前后使用CPS的各组肺出血的发生率,并探讨NRDS严重程度相同的患儿在不同通气模式下肺出血发生率。结果对于重度NRDS患儿,以生后4、5、6、7、8 h作为使用CPS的时间界点时肺出血的发生率比较差异有统计学意义(P<0.05)。对于轻度NRDS患儿,生后5 h内使用组肺出血发生率明显低于5 h后使用组(3.2%vs9.7%,P<0.05)。对于轻度NRDS患儿,以生后5 h为界点,第3组的肺出血发生率明显低于第2组(0.3%vs 6.5%,P<0.05)。结论生后5 h内使用CPS是治疗NRDS时有效降低肺出血发生率的最后时限,对于轻度NRDS,生后5 h内使用CPS联合nCPAP可明显减少肺出血发生率。 Objective Pulmonary hemorrhage (PH) is considered as one of severe adverse events associated with surfactant therapy in the treatment of neonatal respiratory distress syndrome (NRDS). In this multicenter retrospectively study, we wish to find the timing of initial surfactant administration in order to reduce the incidence of PH. Methods Clinical data of 453 NRDS cases treated by calf pulmonary surfactant (CPS) in the Department of Neonatology out of 22 hospitals during May 2008 to June 2009 were collected and reviewed. These neonates were divided into 3 groups: severe NRDS cases treated by CPS and conventional mechanical ventilation(CMV) (group 1), mild NRDS cases treated with CPS and CMV (group 2), and mild RDS cases treated with CPS and nasal continuous positive airway pressure (nCPAP) (group 3). Postnatal hours 1, 2, 3, 4, 5, 6, 7 and 8 were selected as cutoff times, and the incidence of PH at these time points were analyzed. The incidence of PH between group 2 and 3 were also compared. Results For severe NRDS cases, significant differences in the incidence of PH were found when postnatal hours 4, 5, 6, 7 and 8 were selected as the cutoff time (P〈0.05). For mild NRDS cases, the incidence of PH was significantly lower in the neonates receiving CPS within 5 h after birth than those beyond 5 h (3.2% vs 9.7%, P〈0.05). Postnatal hour 5 was selected as the cutoff time for mild NRDS cases, with the incidence of PH obviously lower found in the neonates treated by nCPAP than those by CMV (0.3% vs 6.5%, P〈0.05). Conclusion Postnatal hour 5 is identified as the timing of initial CPS administration to reduce the incidence of PH. For mild NRDS, the incidence of PH is greatly decreased when initial surfactant administration performed within 5 h after birth followed by nCPAP.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2014年第11期1203-1207,共5页 Journal of Third Military Medical University
关键词 新生儿呼吸窘迫综合征 肺出血 肺表面活性物质 多中心研究 neonatal respiratory distress syndrome pulmonary hemorrhage pulmonary surfactant multi-center study
  • 相关文献

参考文献13

  • 1Lin T W, Su B H, Lin H C, et al. Risk factors of pulmonary hemor- rhage in very-low-birth-weight infants: a two-year retrospective study [Jl- Acta Paediatr Taiwan, 2000, 41 (5) : 255 -258.
  • 2Cben Y Y, Wang H P, Lin S M, et al. Pulmonary hemorrhage in very low-birthweight infants: risk factors and management[ J]. Pediatr Int, 2012, 54(6) : 743 -747.
  • 3Jobe A H. Mechanisms to explain surfactant responses[ J]. Biol Neo- nate, 2006, 89(4) : 298 -302.
  • 4Gortner L, Wauer R R, Hammer H, et al. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks ' gestational age : a mul- ticenter controlled clinical trim [ J ]. Pediatrics, 1998, 102 (5) : 1153 - 1160.
  • 5European Exosurf Study Group. Early or selective suffactant ( eolfoscer- il palmitate, Exosuff) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis [ J ]. Online J Curt Clin Trials, 1992, Doe No 28: 3886.
  • 6Alfaleh K, Smyth J A, Roberts R S, et al. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethaein prophylaxis in preterms [J]. Pediatrics, 2008, 121(2): e233-e238.
  • 7Mercier C E, Soll R F. Clinical trials of natural suffaetant extract in re- spiratory distress syndrome[J]. Clin Perinatol, 1993, 20(4) : 711 - 735.
  • 8Haynes R L, Billiards S S, Borenstein N S, et al. Diffuse axonal inju- ry in periventricular leukomalaeia as determined by apoptotie marker fractin[J]. Pediatr Res, 2008, 63(6) : 656 -661.
  • 9An international classification of retinopatby of prematurity. The Corn-mittee for the Classification of Retinopathy of Prematurity [ J ]. Arch Ophthalmol, 1984, 102(8) : 1130-1134.
  • 10Lavoie P M, Pham C, Jang K L. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health[J]. Pediatrics, 2008, 122(3) : 479 -485.

同被引文献168

  • 1Sedigheh GHAEMI Maryam MOHAMADYMASODI Roya KELISHADI.表面活性物质替代治疗新生儿呼吸窘迫综合征的疗效评估(英文)[J].中国当代儿科杂志,2009,11(3):188-190. 被引量:9
  • 2王红雁,迟雁.猪肺磷脂注射液[J].中国新药杂志,2007,16(4):333-334. 被引量:5
  • 3陈超.新生儿呼吸窘迫综合征∥邵肖梅,叶鸿瑁,丘小汕.实用新生儿学.4版.北京:人民卫生出版社,2011:395-398.
  • 4刘传合,董声焕,徐辉,赵建军.两种肺表面活性剂药效的实验比较[J].中国新药杂志,1997,6(2):145-148. 被引量:2
  • 5Tissieres P, Myers P, Beghetti M, et al. Surfactant use based on the oxygenation response to lung recruitment during HFOV in VLBW infants[J], Intensive Care Med, 2010, 36(7) : 1164 -1170.
  • 6Miedema M, de-Jongh F H, Frerichs I, et al. Changes in lung volume and ventilation during surfactant treatment in ventilated preterm infants [J]. Am J Respir Crit Care Med, 2011, 184(1) : 100 -105.
  • 7Kribs A, Devenge J, Hunseler C, et al. Does the combination of primary high-frequency oscillation ventilation and prophylactic surfactant therapy improve the prognosis for extremely low birth weight infants? [J]. Z Geburtshilfe Neonatal, 2004, 208(5) : 190 -196.
  • 8Dani C. Surfactant replacement in preterm infants with respiratory distress syndrome [ J ]. Acta Biomed, 2012, 83 ( Suppl 1 ) : 17 - 20.
  • 9Walsh B K, Daigle B, DiBlasi R M, et al. AARC Clinical Practice Guideline. Surfactant replacement therapy: 2013 [ J ]. Respir Care, 2013, 58(2) : 367 -375.
  • 10Ma C C, Ma S. The role of surfactant in respiratory distress syndrome [J]. Open Respir Med J, 2012, 6:44 -53.

引证文献21

二级引证文献174

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部